WATCH LIVE
timothy sykes logo
Bio-Techne TECH Stock Jumps As Activists And Analysts Clash Thumbnail
G Google News

Bio-Techne TECH Stock Jumps As Activists And Analysts Clash

ELLIS HOBBS•UPDATED JUN. 25, 2026, 5:04 PM ET
Reviewed by Matt Monacoand Fact-checked by Bryce Tuohey

Bio-Techne Corp stocks have been trading up by 21.07 percent amid optimism around its latest biotech innovation and partnerships.

Key Takeaways

  • TD Cowen backed Bio-Techne again with a Buy rating and $65 target, calling TECH a top small/mid-cap idea for 2026 after a modest selloff.
  • Activist fund Ananym Capital is pushing Bio-Techne’s board to run a strategic review, including a possible sale to a larger life science player.
  • Piper Sandler started coverage on TECH at Neutral with a $65 target, then trimmed that target to $60 as macro headwinds linger.
  • Street targets around $61.42 still lean positive, but mixed analyst tones keep traders focused on risk/reward.
  • A new Bio-Techne–Refeyn workflow bundles MauriceFlex and mass photometry to speed and de‑risk complex biologic and biosimilar development.

Candlestick Chart

Live Update At 17:03:48 EDT: On Thursday, June 25, 2026 Bio-Techne Corp stock [NASDAQ: TECH] is trending up by 21.07%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TECH has ripped higher in late June. After grinding between roughly $51 and $58 for most of the 2026/06/01–2026/06/24 window, Bio-Techne closed at $70.70 on 2026/06/25. That’s a sharp breakout from the prior range and a clear momentum shift that aggressive traders watch closely.

Intraday on 2026/06/25, TECH barely dipped below $70 and spent most of the day in a tight band around $70.50–$70.90. That tells you dip buyers stepped in quickly and sellers backed off, classic behavior after a news-driven re‑rating. For short-term traders, that kind of tight consolidation near highs often acts like a coiled spring.

More Breaking News

Fundamentally, Bio-Techne is a high‑margin, premium‑multiple name. Gross margin sits around 65%, with EBITDA margin above 20%, and the most recent quarter showed about $311.4M in revenue and $51.0M in net income. Cash generation is solid too, with roughly $77.6M in free cash flow and a light balance sheet: current ratio near 4.5 and total debt to equity only about 0.14. The flip side is valuation. TECH trades on a rich ~79x price/earnings and about 7.1x sales, so any wobble in growth or guidance can hit the stock hard. This is a classic “quality but not cheap” setup where price action matters as much as fundamentals.

Why Traders Are Watching TECH Right Now

The story around TECH right now is a tug‑of‑war between macro fear and company‑specific catalysts, and that’s exactly the kind of tape active traders look for.

On the bullish side, TD Cowen just reiterated its Buy rating on Bio-Techne, naming TECH a top small/mid‑cap idea for 2026 with a $65 price target. They argue the stock is underappreciated after a modest year‑to‑date pullback and should benefit as demand in life science tools improves into fiscal 2027. With TECH already trading near or above that target after the recent squeeze, this tells traders how fast sentiment has flipped.

The activist angle adds more fuel. Ananym Capital Management has taken a stake in Bio-Techne and is pressuring the board to run a full strategic review, including a possible sale to a larger industry player. For TECH traders, activism often means one thing: potential catalysts. A sale process, breakup rumors, or even modest governance changes can all drive sharp, tradable swings as the market handicaps outcomes.

Piper Sandler sits on the cautious side of the ledger. The firm initiated Bio-Techne at Neutral with a $65 target, pointing to macro headwinds in biotech and academic spending and China exposure across life science tools. Then it cut that target to $60 while staying Neutral, even as the wider Street remains broadly Overweight with an average target around $61.42. That split view helps explain why TECH was stuck in a range before this latest breakout – traders were waiting for a clear signal.

The product story is more quietly constructive. Bio-Techne’s collaboration with UK‑based Refeyn combines the MauriceFlex icIEF fractionation system with Refeyn’s mass photometry into a single, roughly four‑hour workflow. For biopharma clients, that means fewer samples, earlier detection of antibody and protein flaws, and faster development of complex biologics and biosimilars. TECH is leaning into higher‑value, technical niches, which supports the long‑term growth narrative even if the near‑term macro picture is choppy.

Conclusion

For active traders, TECH now sits at the intersection of strong chart momentum, activist pressure, and a mixed but engaged analyst community. Bio-Techne’s recent quarter showed solid profitability and cash flow, backed by a strong balance sheet and high margins. That financial base gives activists like Ananym Capital room to argue there is more value to unlock, whether through sharper execution or a sale to a larger life science player.

At the same time, the rich valuation and Piper Sandler’s Neutral stance with a trimmed $60 target remind traders not to ignore macro risk. Weak biotech funding, tighter academic budgets, and China exposure are very real overhangs for TECH and its peers. If those trends worsen, a high‑multiple chart like Bio-Techne’s can correct fast.

The innovation pipeline, including the first‑of‑its‑kind Refeyn workflow, leans the other way. It shows TECH is not just riding sector beta; it is building tools that directly attack pain points in biologics and biosimilar development. That kind of edge can support premium pricing and recurring demand once spending cycles normalize.

For traders studying TECH, the playbook is to respect both the upside catalysts and the downside volatility. As Tim Sykes loves to hammer home, “Patterns repeat, but only for traders who are prepared and disciplined enough to act.” As millionaire penny stock trader and teacher Tim Sykes, says, “Preparation plus patience leads to big profits.”. This entire discussion is for educational and research purposes only, but the current setup around Bio-Techne gives plenty of patterns – on the chart, in the news, and in the fundamentals – for disciplined traders to study.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”